SynthesisFEBS open bio2019
YAP1 overexpression is associated with poor prognosis of breast cancer patients and induces breast cancer cell growth by inhibiting PTEN.
Synthesis in FEBS open bio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Basroparib inhibits YAP-driven cancers by stabilizing angiomotin.Molecular oncology · 2026Article
- Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications.Translational lung cancer research · 2025Article
- Article
- Molecular dynamics simulations of a multicellular model with cell-cell interactions and Hippo signaling pathway.PLoS computational biology · 2024Article
- Elevated expression of ELK1 promotes breast cancer cell growth and correlates with poor prognosis of breast cancer patients.Annals of medicine and surgery (2012) · 2024Article
- Upregulation of YPEL3 expression and induction of human breast cancer cell death by microRNAs.Toxicological research · 2024Article
- Asiaticoside inhibits breast cancer progression and tumor angiogenesis via YAP1/VEGFA signal pathway.Heliyon · 2024Article
- TM4SF19 controls GABP-dependentProceedings of the National Academy of Sciences of the United States of America · 2024Article
- YAP Signaling Regulates the Cellular Uptake and Therapeutic Effect of Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- α-Catenin acetylation is essential for its stability and blocks its tumor suppressor effects in breast cancer through Yap1.Cancer gene therapy · 2023Article
- YAP1 Expression in HR+HER2- Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation.Cancers · 2023Article
- YPEL3 expression induces cellular senescence via the Hippo signaling pathway in human breast cancer cells.Toxicological research · 2023Article
- Integrative analysis identifies two molecular and clinical subsets in Luminal B breast cancer.iScience · 2023Article
- Transcription factor glucocorticoid modulatory element-binding protein 1 promotes hepatocellular carcinoma progression by activating Yes-associate protein 1.World journal of gastrointestinal oncology · 2023Article
- ATXN3 deubiquitinates YAP1 to promote tumor growth.American journal of cancer research · 2023Article
- Article
- Yes-associated protein-1 overexpression in ocular surface squamous neoplasia; a potential diagnostic marker and therapeutic target.Frontiers in oncology · 2023Article
- YAP1 and P53 Expression in Papillary Thyroid Carcinoma.Iranian journal of pathology · 2023Article
- Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
YES-associated protein 1 (YAP1) plays a key role as a transcriptional coactivator in the Hippo tumor suppressor pathway. YAP1 is overexpressed in a variety of cancers and is considered to be encoded by a proto-oncogene. However, the role of YAP1 remains debatable, because both gain and loss of YAP1 expression have both been reported in breast cancer (BC). Here, we found that elevated expression of YAP1 mRNA in BC was negatively correlated with relapse-free, distant metastases-free and overall survival rates. We then knocked down or overexpressed YAP1 in human BC cells, and examined cell proliferation, apoptosis, and tumorigenic ability
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.